Author(s): Lau D, Fedinands M, Leung L, Fullinfaw R, Kong D,
Abstract Share this page
Abstract OBJECTIVE: To determine the therapeutic efficacy of adjuvant use of voriconazole, 1\%, eyedrops in the treatment of refractory fungal keratitis. METHODS: A prospective open-label trial was conducted to determine voriconazole levels obtained in human aqueous humor after administration of a 1\% solution, preserved with 0.01\% benzalkonium chloride, every 6 hours for 3 days, or hourly for 4 doses. Ten participants were selected among patients scheduled to undergo elective anterior segment surgery, and samples were tested using validated high-performance liquid chromatography. RESULTS: The mean (SD) voriconazole concentrations after hourly dosing (n = 5) was 1.90 (1.12) microg/mL and after a single dosing every 6 hours (n = 5) was 0.94 (1.21) microg/mL, respectively. The mean (SD) sampling times after the last administration of eyedrops were 1.1 (0.5) hours after hourly dosing and 2.1 (0.6) hours after a single dosing every 6 hours. CONCLUSIONS: Voriconazole, 1\%, eyedrops are well tolerated and penetrate into human aqueous humor when administered at hourly or 6-hourly intervals. They are effective in treating Candida and Aspergillus keratitis, are substantially more affordable than oral therapy, and have less potential to cause systemic adverse effects.
This article was published in Arch Ophthalmol
and referenced in Fungal Genomics & Biology